Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Works by Tang, Zhongwhen
Results: 2
1
2
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody targeting the DR5 receptor.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2015, v. 75, n. 5, p. 887, doi. 10.1007/s00280-015-2712-0
- By:
- Publication type:
- Article